EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
HC Wainwright Has Optimistic Outlook of BioNTech Q2 Earnings
HC Wainwright Reiterates Buy Rating for BioNTech (NASDAQ:BNTX)
WATCH: Synergy in science-navigating the landscape of pharmaceutical collaborations
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders | Morningstar
Q4 Earnings Forecast for BioNTech Issued By HC Wainwright
Big Pharma CEOs rake in millions in compensation while patients struggle with sky-high drug prices - NaturalNews.com
HC Wainwright Has Negative Outlook for BioNTech Q4 Earnings
ADC cancer drugs: Pfizer, AstraZeneca, Merck bet on chemo replacement
BioNTech (NASDAQ:BNTX) Price Target Cut to $138.00 by Analysts at HC Wainwright
Covington, Hengeler, Skadden and Latham Advise on BioNTech's $1.25B Takeover of German Rival
BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages
BioNTech's CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN) | Morningstar
CureVac downgraded to Hold from Buy at Jefferies | Markets Insider
Health Care Climbs Amid Deal Activity - Health Care Roundup | Morningstar
Dow Jones Top Company Headlines at 1 PM ET: Micron Technology to Invest $200 Billion in U.S. Semiconductor Manufacturing | BioNTech ... | Morningstar
Citi's Metzger on Asia Pacific's M&A, IPO Rush: Bloomberg Deals
Dow Jones Top Company Headlines at 11 AM ET: Micron Technology to Invest $200 Billion in U.S. Semiconductor Manufacturing | BioNTech ... | Morningstar
International business briefs: Syrians to go full crypto
Dow Jones Top Company Headlines at 9 AM ET: BioNTech to Buy CureVac in Stock Deal Valued Around $1.25 Billion | Tesco ... | Morningstar
BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus | Markets News - Business Standard
BioNTech to acquire CureVac in $1.25 billion all-stock deal
BioNTech To Acquire CureVac In All-stock Deal With Aggregate Equity Value Of Approx. $1.25 Bln
Biontech's $1.25B Curevac buyout removes mRNA lawsuit uncertainty | BioWorld
Wall Street Zen Upgrades BioNTech (NASDAQ:BNTX) to Hold
Equities Analysts Offer Predictions for BioNTech Q1 Earnings
TB Alternative Assets Ltd. Acquires Shares of 38,996 BioNTech SE (NASDAQ:BNTX)
BioNTech (NASDAQ:BNTX) Price Target Raised to $145.00
BioNTech (NASDAQ:BNTX) Upgraded at Wall Street Zen
HC Wainwright Forecasts Strong Price Appreciation for BioNTech (NASDAQ:BNTX) Stock
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | The Manila Times
)
AstraZeneca, BioNTech and CIC back Sortera Bio's £7.5m pre-seed round
Truist Lifts BioNTech (BNTX) Price Target After New Partnership
Healthy Returns: AstraZeneca, Pfizer, Gilead release cancer drug data
Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment
BioNTech (NASDAQ:BNTX) Sees Large Volume Increase - Here's Why
BioNTech (NASDAQ:BNTX) Shares Gap Up - Time to Buy?
BioNTech (NASDAQ:BNTX) Given Buy Rating at Truist Financial
Dow Jones Top Company Headlines at 3 AM ET: TSMC Sees Limited Tariff Impact on AI Strength | How ... | Morningstar
Why BioNTech SE (BNTX) Skyrocketed On Monday
Dow Jones Top Company Headlines at 1 AM ET: How Moderna Went From Pandemic Hero to Vaccine Victim | Paramount ... | Morningstar
Dow Jones Top Company Headlines at 11 PM ET: How Moderna Went From Pandemic Hero to Vaccine Victim | Paramount ... | Morningstar
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies
Dow Jones Top Company Headlines at 7 PM ET: Walt Disney Co. to Lay Off Hundreds | Jamie ... | Morningstar
These 10 Stocks Blew Past Expectations
Dow Jones Top Company Headlines at 5 PM ET: Walt Disney Co. to Lay Off Hundreds | Jamie ... | Morningstar
Bristol Myers' cancer deal is promising, but doesn't change our stance on stock yet
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol-Myers and BioNTech: Oncology Collaboration Further Solidifies BNT327's Potential | Morningstar
Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal
Dow Jones Top Company Headlines at 9 AM ET: Campbell's Posts Higher Sales as Consumers Return to Cooking at Home | BioNTech ... | Morningstar
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race | Morningstar
Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (2)
Bristol Myers to help develop cancer drug in BioNTech partnership
BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion | Morningstar
Bristol Myers to Pay $1.5B for BioNTech Cancer Drug Deal | Newsmax.com
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | The Manila Times
Bristol-Myers to Pay BioNTech Up to $11.1 Billion in Cancer Deal
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | Morningstar
BioNTech, Bristol Myers Ink Strategic Partnership To Co-Develop BNT327 For Several Solid Tumor Type
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+ | BioWorld
Wall Street Zen Downgrades BioNTech (NASDAQ:BNTX) to Sell
BioNTech (NASDAQ:BNTX) Shares Gap Down - Time to Sell?
BioNTech news
Latest news
Show more
MSTR Stock News: MSTR Shares Rise 1.9% Amid Mixed Options Market Sentiment
Stock indexes today: Dow Jumps 500 Points, S&P 500 Rises on Trump Ceasefire
Value of bitcoin today: BTC/USD over 106K as Middle East tensions eased
